Guía de Práctica Clínica (GPC) Nacional de Prevención, Diagnóstico y Tratamiento de la Hipertensión Arterial 2019: Versión breve para el equipo de salud

Objectives

Argentina’s Ministry of Health guideline supports implementation of the 2019 National Clinical Practice Guideline for prevention, diagnosis and treatment of hypertension, seeking to improve care quality for adults aged 18 years and over, principally in outpatient primary care. It contributes to the National Plan for the Prevention and Control of Hypertension and to the World Health Organization and Pan American Health Organization HEARTS initiative, which aims to reduce premature cardiovascular mortality among people aged 30 to 69 years by 30% by 2030.[1][2][3][4]

• Reduce hypertension, cardiovascular risk, morbidity, mortality and associated social and healthcare costs through prevention, timely diagnosis, effective treatment and sustained control.[2][5][6]
• Promote healthy lifestyles, including regular physical activity, balanced diets low in sodium, healthy weight, tobacco cessation, limited alcohol consumption, stress management and reduced sedentary behaviour.[7][8][9][5][10]
• Screen adults for hypertension and diagnose it through standardised repeated office blood-pressure measurements, while using home or ambulatory monitoring where clinically indicated.[11][12][13][14]
• Achieve office blood pressure below 140/90 mmHg for most adults aged 18 to 79 years, consider targets near 130/80 mmHg for people at high cardiovascular risk who tolerate treatment, and use below 150/90 mmHg for people starting treatment at age 80 or above.[7][15][16]
• Detect target-organ damage, including cardiac and renal abnormalities, and intensify treatment towards stricter targets close to 130/80 mmHg where appropriate.[17][18][19]
• Strengthen adherence, person-centred self-management and management of comorbidities including diabetes, chronic kidney disease, coronary disease, obesity, anxiety and depression.[20][21][22][23]
• Distinguish hypertensive urgency, emergency and pseudocrisis, supporting safe outpatient management of urgency while ensuring immediate emergency assessment when acute target-organ injury is suspected.[24][25]

Implementation

Implementation combines standardised, evidence-based clinical protocols with interdisciplinary, primary-care-centred delivery. The Ministry of Health and its National Directorate for the Comprehensive Approach to Non-Communicable Diseases developed and sponsor the guideline, while HEARTS frames service delivery around healthy lifestyles, simplified protocols, essential medicines and technologies, cardiovascular-risk management, team-based care and monitoring.[1][3][4]

• Use validated automatic upper-arm monitors where available, standardise patient preparation and positioning, take repeated unrounded readings, and diagnose office hypertension from averaged measurements of at least 140/90 mmHg at consultations on different days.[12][13][26][14]
• Apply age- and risk-based screening intervals, with at least annual measurement for people over 40 years, those with risk factors, or people with borderline readings; consider measurement at every contact with health services.[12]
• Use home monitoring with patient training and validated devices, and reserve 24-hour ambulatory monitoring as the reference method when white-coat or masked hypertension is suspected or diagnostic clarification is needed.[14][15]
• Deliver lifestyle support through individual, household and population measures, including sodium-reduction actions, food labelling and awareness activity; encourage at least 150 minutes of moderate physical activity weekly and a maximum intake of 5 grams of salt, equivalent to 2 grams of sodium, daily.[8][5][27]
• Provide tobacco-cessation support through routine identification and clinical recording of tobacco use, brief or intensive behavioural interventions, follow-up, and medicines such as nicotine replacement, bupropion or varenicline where appropriate.[9][28]
• Assess obesity through body-mass index and waist circumference, manage it through interdisciplinary care, and support an initial weight-loss goal of 5% to 10% of baseline weight over six to 12 months.[29][9]
• Screen for probable anxiety and depression using the Generalised Anxiety Disorder 7-item scale and Patient Health Questionnaire-9, respectively, and offer referral to the Ministry of Health’s Línea Salud Responde telephone service where needed.[30][31]
• Start pharmacological treatment with recommended first-line groups, namely angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, calcium-channel blockers, thiazide or thiazide-like diuretics, and beta-blockers in specified circumstances. Escalate monthly when adherence is adequate, generally favouring low- or medium-dose combinations and once-daily fixed-dose tablets where available.[7][6][32][20]
• Avoid combining angiotensin-converting enzyme inhibitors with angiotensin-receptor blockers, and avoid both classes in women of childbearing potential because of adverse-effect and fetal risks.[6][20][4]
• Use a simple HEARTS treatment pathway in primary care, with assessment of adherence and adverse effects before each intensification step and referral to secondary care when control is not achieved.[4]
• Organise care through interdisciplinary teams with defined roles, training, flowcharts, information and communication technologies, active follow-up, patient education and support for self-management.[22][33]
• Use brief adherence interventions, motivational interviewing and shared goal-setting to identify barriers, strengthen confidence and tailor behavioural and medicines support.[33][23][34]
• Assess target-organ damage within the first year after diagnosis using electrocardiography, estimated glomerular filtration rate and urine albumin-to-creatinine ratio; use echocardiography where indicated and refer people with significant renal, albuminuria or electrocardiographic abnormalities.[17][35][18]
• Manage hypertensive urgency outside hospital when there are no symptoms or signs of acute target-organ injury, using rest, oral treatment initiation or intensification, gradual reduction, warning signs and frequent follow-up.[24][36][25]

Monitoring & Evaluation

Monitoring is primarily clinical and embedded in routine primary-care hypertension management, with standardised blood-pressure measurement, diagnostic confirmation, treatment review and follow-up of cardiovascular risk, adherence and target-organ damage. HEARTS includes monitoring systems as a core implementation component, but the extracts do not establish a national indicator set, reporting timetable, audit process, surveillance architecture or formal accountability arrangements.[3][4]

• Measure clinic blood pressure using repeated, averaged, unrounded readings under standardised conditions, preferably with validated automatic upper-arm devices. Diagnose office hypertension from readings of at least 140/90 mmHg at consultations on different days.[13][26][14]
• Screen adults periodically according to age, blood-pressure level and risk profile: at least every three to five years for people aged 18 to 40 without risk factors and with readings at or below 130/80 mmHg, and at least annually for people over 40, those with risk factors or those with borderline readings. Measuring blood pressure at each health-system contact is presented as a practical option.[12]
• Use home monitoring or 24-hour ambulatory monitoring when white-coat or masked hypertension is suspected. Home monitoring should include averaged readings over at least four days, ideally seven, with device memory retained where available to support accurate reporting.[13][14][15]
• Apply method-specific diagnostic thresholds: at least 140/90 mmHg in the office, 135/85 mmHg for home-monitoring averages, and ambulatory averages of at least 135/85 mmHg by day, 120/70 mmHg at night or 130/80 mmHg over 24 hours.[14]
• Review treatment response monthly, assess adherence before intensifying medication, monitor adverse effects and escalate or refer to secondary care when the standard primary-care pathway does not achieve control.[6][32][4]
• Track treatment adherence through active follow-up, patient-centred support and, where appropriate, instruments such as the Morisky-Green and Haynes-Sackett questionnaires. Team performance assessment and repeated brief adherence interventions are included in the interdisciplinary care model.[22][33][23]
• Monitor lifestyle-related clinical outcomes, including achievement and maintenance of blood pressure below 140/90 mmHg within generally three to six months for eligible people initially managed through lifestyle measures alone. Track weight reduction against an initial target of 5% to 10% of baseline weight over six to 12 months.[27][9]
• Record tobacco use and exposure to environmental tobacco smoke in the clinical record, provide cessation follow-up, and measure blood pressure before and during bupropion treatment, particularly when it is combined with nicotine replacement.[9][28]
• Assess psychosocial factors using the Generalised Anxiety Disorder 7-item scale and Patient Health Questionnaire-9 where appropriate. The Generalised Anxiety Disorder 7-item scale cut-off of 10 is reported to have 86.8% sensitivity and 93.4% specificity for probable generalised anxiety disorder.[30]
• Assess frailty in older people or those with vulnerability using the FRAIL tool or Short Physical Performance Battery. A Short Physical Performance Battery score below 10 indicates frailty or vulnerability.[37][38]
• Investigate target-organ damage within the first year after hypertension diagnosis using electrocardiography, estimated glomerular filtration rate and morning urine albumin-to-creatinine ratio. Refer for further assessment when albuminuria is at least 30 mg/g on two measurements, estimated glomerular filtration rate is below 60 ml/min/1.73 m², or electrocardiography suggests damage.[17][35]
• Repeat electrocardiography, renal function and urine albumin assessment annually when target-organ damage is present and every one to three years when absent; perform echocardiography every two to three years when damage is present.[19][39]
• Use frequent follow-up for hypertensive urgency managed as an outpatient, assess symptoms and signs of acute target-organ injury rather than blood-pressure values alone, and avoid excessively rapid blood-pressure reduction.[24][36][25]
• Interpret population data as indicating an important care gap: 2015/16 Argentine estimates reported that 38.8% of people with hypertension were unaware of their diagnosis and 24.2% were controlled.[22]

Costing & Financing

The extracts identify relative resource implications of diagnostic and follow-up methods but provide no budget, costing methodology, unit price, financing source, allocation, resource-mobilisation plan, funding gap or quantified economic assumption.[1][3][40]

• Prioritise clinic blood-pressure measurement as a low-cost and broadly available approach; home and ambulatory monitoring are described as less available and more costly, without monetary values.[28][12]
• Recognise that ambulatory blood-pressure monitoring is more costly and less available than alternative measurement approaches.[15]
• Use electrocardiography as a relatively low-cost investigation where appropriate, while recognising that echocardiography is more costly, less accessible and dependent on trained personnel.[35][18]
• Use formula-based estimates of glomerular filtration in routine practice because direct measurement methods are complex and costly.[35]
• Consider the resource consequences of more frequent investigations, which may increase healthcare costs and inconvenience patients, although no monetary estimate is supplied.[19]
• Note that single-tablet, once-daily combinations are preferred where available to support adherence, but the extracts provide no prices or affordability analysis for medicines.[32][20]